Medians and Milestones in Describing the Path to Cancer Cures Telling "Tails"

被引：37

作者：

Hellmann, Matthew D. ^{[1
,2
]}

Kris, Mark G. ^{[1
,2
]}

Rudin, Charles M. ^{[1
,2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA

[2] Weill Cornell Med Coll, New York, NY USA

来源：

JAMA ONCOLOGY | 2016年 / 2卷 / 02期

关键词：

CELL LUNG-CANCER; ADVANCED MELANOMA; PHASE-III; SURVIVAL;

D O I：

10.1001/jamaoncol.2015.4345

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

收藏

页码：167 / 168

页数：2

相关论文

共 8 条

[1]

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS) [J].

Fukuoka, Masahiro ;

Wu, Yi-Long ;

Thongprasert, Sumitra ;

Sunpaweravong, Patrapim ;

Leong, Swan-Swan ;

Sriuranpong, Virote ;

Chao, Tsu-Yi ;

Nakagawa, Kazuhiko ;

Chu, Da-Tong ;

Saijo, Nagahiro ;

Duffield, Emma L. ;

Rukazenkov, Yuri ;

Speake, Georgina ;

Jiang, Haiyi ;

Armour, Alison A. ;

To, Ka-Fai ;

Yang, James Chih-Hsin ;

Mok, Tony S. K. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (21) :2866-2874

[2]

GOULD SJ, 1985, DISCOVER, V6, P40

[3]

Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial [J].

Maio, Michele ;

Grob, Jean-Jacques ;

Aamdal, Steinar ;

Bondarenko, Igor ;

Robert, Caroline ;

Thomas, Luc ;

Garbe, Claus ;

Chiarion-Sileni, Vanna ;

Testori, Alessandro ;

Chen, Tai-Tsang ;

Tschaika, Marina ;

Wolchok, Jedd D. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (10) :1191-1196

[4]

Cure Models as a Useful Statistical Tool for Analyzing Survival [J].

Othus, Megan ;

Barlogie, Bart ;

LeBlanc, Michael L. ;

Crowley, John J. .

CLINICAL CANCER RESEARCH, 2012, 18 (14) :3731-3736

[5]

Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls [J].

Pocock, SJ ;

Clayton, TC ;

Altman, DG .

LANCET, 2002, 359 (9318) :1686-1689

[6]

New Challenges in Endpoints for Drug Development in Advanced Melanoma [J].

Ribas, Antoni ;

Hersey, Peter ;

Middleton, Mark R. ;

Gogas, Helen ;

Flaherty, Keith T. ;

Sondak, Vernon K. ;

Kirkwood, John M. .

CLINICAL CANCER RESEARCH, 2012, 18 (02) :336-341

[7]

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer [J].

Rizvi, Naiyer A. ;

Hellmann, Matthew D. ;

Snyder, Alexandra ;

Kvistborg, Pia ;

Makarov, Vladimir ;

Havel, Jonathan J. ;

Lee, William ;

Yuan, Jianda ;

Wong, Phillip ;

Ho, Teresa S. ;

Miller, Martin L. ;

Rekhtman, Natasha ;

Moreira, Andre L. ;

Ibrahim, Fawzia ;

Bruggeman, Cameron ;

Gasmi, Billel ;

Zappasodi, Roberta ;

Maeda, Yuka ;

Sander, Chris ;

Garon, Edward B. ;

Merghoub, Taha ;

Wolchok, Jedd D. ;

Schumacher, Ton N. ;

Chan, Timothy A. .

SCIENCE, 2015, 348 (6230) :124-128

[8]

ATTITUDES TO CHEMOTHERAPY - COMPARING VIEWS OF PATIENTS WITH CANCER WITH THOSE OF DOCTORS, NURSES, AND GENERAL PUBLIC [J].

SLEVIN, ML ;

STUBBS, L ;

PLANT, HJ ;

WILSON, P ;

GREGORY, WM ;

ARMES, PJ ;

DOWNER, SM .

BRITISH MEDICAL JOURNAL, 1990, 300 (6737) :1458-1460